Scinai Immunotherapeutics Ltd.
SCNINASDAQHealthcare● Active
$0.41
$-0.00(-1.14%)
Market Cap$536143
P/E Ratio—
52W High$3.48
52W Low$0.367
Scinai Immunotherapeutics Ltd. (SCNI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SCNI · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.31M | $0.66M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $3.96M | $1.24M | $0.51M | $0.56M | $0.75M |
| Gross Profit | ($2.65M) | ($0.58M) | ($0.51M) | ($0.56M) | ($0.75M) |
| Gross Margin %(computed) | -202.29% | -88.15% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $2.37M | $5.53M | $5.21M | $5.76M | $3.25M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $7.72M |
| Total Operating Expenses | $4.89M | $8.06M | $9.71M | $11.06M | $10.86M |
| Operating Income | ($7.54M) | ($8.64M) | ($9.71M) | ($11.06M) | ($10.87M) |
| Operating Margin %(computed) | -575.29% | — | — | — | — |
| Interest Income | $0.02M | $0.10M | $0.12M | $8.10M | $0.00M |
| Interest Expense | $0.36M | $1.44M | $0.01M | $5.05M | $3.36M |
| Income Before Tax | ($8.31M) | $4.80M | ($6.50M) | ($5.80M) | ($8.21M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($8.31M) | $4.80M | ($6.50M) | ($5.80M) | ($8.21M) |
| Net Margin %(computed) | -633.64% | 728.88% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.60 | $6.00 | $-16.80 | $-30.80 | $-80.00 |
| Wtd Avg Shares | 2.33M | 0.81M | 0.39M | 0.19M | 0.10M |
| EBITDA | ($6.53M) | ($6.99M) | ($9.19M) | ($10.50M) | ($10.39M) |
| EBITDA Margin %(computed) | -497.86% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Scinai Immunotherapeutics Ltd. data
About Scinai Immunotherapeutics Ltd. (SCNI) Income Statement
Scinai Immunotherapeutics Ltd. (SCNI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SCNI reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -202.29%), and net income of ($0.01B) — a net profit margin of -633.64%.
Frequently asked questions
SCNI · 4 questionsScinai Immunotherapeutics Ltd. (SCNI) reported revenue of $0.00B for 2025, up 99.2% year-over-year.
SCNI revenueSCNI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09